Acute toxicity at that scale can cause severe digestive and neurological symptoms, hair loss, tremors, kidney failure, heart failure and, rarely, death
Survodutide (BI 456906) is a GLP-1/glucagon co-agonist which has progressed to phase 3 clinical trials as treatment for obesity (SYNCHRONIZE programme)
Here is how that plays out, step by step
All these ads are nauseating because they traffic in the assumption that weight loss is a universal goal
Must be taken on an empty stomach at least 30 minutes before first food, beverage, or other oral medications, with no more than 4 oz (120 ml) of plain water other liquids reduce absorption
Notifications about medical policy updates can be found under the Recent Updates section on the Alerts and Updates page